+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA Vaccine Raw Materials Market - Global Forecast 2026-2032- Product Image
mRNA Vaccine Raw Materials Market - Global Forecast 2026-2032- Product Image
Sale

mRNA Vaccine Raw Materials Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6145721
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The mRNA Vaccine Raw Materials Market is projected to reach USD 3.56 Billion in 2026. It is expected to continue growing at a CAGR of 12.47%, reaching USD 7.25 Billion by 2032.

mRNA Vaccine Raw Materials: Executive Overview

mRNA vaccine raw materials encompass nucleosides, nucleotides, lipids, enzymes, plasmid DNA, buffers, filtration inputs, and single-use manufacturing components. Their strategic importance is shaped by product quality, supply continuity, regulatory compliance, and the ability to support rapid, reproducible manufacturing. The market is therefore best understood through its role in platform readiness and biopharmaceutical resilience rather than through volume alone.

Supply Resilience Is Reshaping Raw-Material Strategy

The landscape is shifting from narrowly optimized procurement toward diversified, qualified, and traceable supply networks. Manufacturers are placing greater emphasis on dual sourcing, regional production capabilities, validated alternatives, cold-chain reliability, and early quality agreements. Regulatory expectations for consistency, impurity control, sterility assurance, and documented change management are also increasing the importance of supplier qualification and lifecycle oversight.

Artificial Intelligence Strengthens Quality and Operational Decisions

Artificial intelligence can improve demand sensing, batch-record review, deviation triage, inventory prioritization, and process-parameter analysis across mRNA raw-material operations. Its value is cumulative when combined with laboratory information, enterprise resource planning, and manufacturing data. Adoption still requires validated models, data governance, cybersecurity controls, human review, and clear accountability, particularly where algorithmic outputs could influence release, supplier approval, or process changes.

Regional Dynamics Reflect Different Manufacturing Priorities

North America combines advanced biomanufacturing infrastructure with strong attention to domestic resilience and regulatory control. Europe emphasizes harmonized quality systems, sustainability, and coordinated supply security across national borders. Asia-Pacific is expanding capabilities in nucleic-acid manufacturing, lipid chemistry, and contract development while serving diverse domestic and export needs. Latin America is focused on technology access, local production capacity, and dependable import channels. The Middle East is investing in life-science infrastructure and strategic manufacturing partnerships, while Africa’s priorities include access, technology transfer, workforce development, and reliable distribution.

Multilateral Groups Shape Standards, Access, and Resilience

ASEAN economies are strengthening regional pharmaceutical cooperation while addressing varied regulatory maturity and manufacturing capacity. BRICS members bring substantial scientific, industrial, and public-health capabilities but require coordinated approaches to standards and cross-border supply. The European Union supports common regulatory structures and strategic autonomy initiatives. G7 countries influence advanced research, quality expectations, and resilience policy. GCC states are developing healthcare and manufacturing ecosystems, whereas NATO members place additional emphasis on preparedness, secure logistics, and continuity of critical supplies.

Country Capabilities Range from Platform Leaders to Emerging Producers

The United States, Canada, the United Kingdom, Germany, France, Italy, Spain, Japan, South Korea, China, India, and Australia each contribute combinations of research, manufacturing, regulation, and healthcare capacity, with differing strengths in lipid systems, nucleic-acid chemistry, fill-finish, analytical testing, and supply-chain management. Brazil and Mexico are important Latin American manufacturing and distribution hubs. Russia retains scientific and pharmaceutical capabilities but faces constraints linked to trade, technology access, and supply-chain integration. Country-level readiness depends on infrastructure, skilled personnel, regulatory alignment, and access to qualified inputs.

Prioritize Qualification, Redundancy, and Data-Enabled Control

Industry leaders should map critical raw materials to qualified suppliers, identify single points of failure, and establish risk-based alternatives before shortages occur. Long-term quality agreements should define specifications, notification periods, audit rights, testing responsibilities, and change-control procedures. Organizations should also invest in regional manufacturing partnerships, robust inventory policies, supplier cybersecurity, and analytical comparability programs. Artificial intelligence should be introduced through controlled use cases with validated data, documented human oversight, and measurable quality and service outcomes.

Methodology: Evidence-Based Assessment of the Supply Ecosystem

This executive summary uses a structured qualitative assessment of the mRNA vaccine raw-material ecosystem. The analysis considers material categories, manufacturing dependencies, quality and regulatory requirements, supply-chain resilience, technology adoption, regional conditions, group-level cooperation, and country capabilities. Findings are framed around observable industry drivers and constraints, without presenting market estimates, market sizing, market shares, or forecasts. Geographic comparisons reflect differences in infrastructure, policy, scientific capacity, and access conditions.

Resilient Inputs Will Define mRNA Platform Readiness

The strategic priority for mRNA vaccine raw materials is dependable, compliant, and adaptable supply. Organizations that combine supplier diversification, rigorous quality systems, regional collaboration, transparent traceability, and carefully governed artificial intelligence will be better positioned to support rapid manufacturing response. Progress will depend not only on chemistry and production capacity, but also on coordinated regulation, skilled workforces, secure logistics, and sustained investment in resilient biopharmaceutical ecosystems.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. mRNA Vaccine Raw Materials Market, by Material Type
7.1. Introduction
7.2. Buffers
7.2.1. Hepes
7.2.2. Phosphate Buffer
7.2.3. Tris Buffer
7.3. Capping Enzymes
7.4. Lipids
7.4.1. Cholesterol
7.4.2. Ionizable Lipids
7.4.3. Pegylated Lipids
7.4.4. Structural Lipids
7.5. Nucleotide Triphosphates
7.5.1. ATP
7.5.2. CTP
7.5.3. GTP
7.5.4. UTP
7.6. Purification Resins
7.6.1. Affinity
7.6.2. Ion Exchange
7.7. Salt Reagents
7.7.1. Potassium Chloride
7.7.2. Sodium Chloride
7.8. Solvents
7.8.1. Ethanol
7.8.2. Isopropanol
8. mRNA Vaccine Raw Materials Market, by Delivery System
8.1. Introduction
8.2. Exosome Based
8.2.1. Engineered Exosomes
8.2.2. Natural Exosomes
8.3. Lipid Nanoparticles
8.3.1. Ionizable Lipid Particles
8.3.2. Pegylated Lipid Particles
8.4. Peptide Based
8.4.1. Cell Penetrating Peptides
8.4.2. Fusogenic Peptides
8.5. Polymeric Nanoparticles
8.5.1. Chitosan Particles
8.5.2. PLGA Particles
9. mRNA Vaccine Raw Materials Market, by Process Stage
9.1. Introduction
9.2. Capping
9.3. Filling And Finishing
9.4. Formulation
9.5. Purification
9.6. Synthesis
10. mRNA Vaccine Raw Materials Market, by Application
10.1. Introduction
10.2. Infectious Diseases
10.2.1. COVID-19 Vaccines
10.2.2. Influenza Vaccines
10.3. Oncology
10.3.1. Hematologic Vaccine
10.3.2. Solid Tumor Vaccines
11. mRNA Vaccine Raw Materials Market, by End Use
11.1. Introduction
11.2. Human Vaccines
11.3. Veterinary Vaccines
12. mRNA Vaccine Raw Materials Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. mRNA Vaccine Raw Materials Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. mRNA Vaccine Raw Materials Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AGC Inc.
16.2. BioNTech SE
16.3. Catalent, Inc.
16.4. CureVac N.V.
16.5. Cytiva Life Sciences
16.6. Danaher Corporation
16.7. FUJIFILM Holdings Corporation
16.8. Ginkgo Bioworks Holdings, Inc.
16.9. Lonza Group AG
16.10. Maravai LifeSciences Holdings, Inc.
16.11. Merck KGaA
16.12. Moderna, Inc.
16.13. Novartis AG
16.14. Pfizer Inc.
16.15. Repligen Corporation
16.16. Sanofi S.A.
16.17. Sartorius AG
16.18. Thermo Fisher Scientific Inc.
16.19. TriLink BioTechnologies
16.20. WuXi Biologics Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global mRNA Vaccine Raw Materials Market, Years Considered for the Study
FIGURE 2. Global mRNA Vaccine Raw Materials Market, Research Design
FIGURE 3. Global mRNA Vaccine Raw Materials Market, Research Framework
FIGURE 4. Global mRNA Vaccine Raw Materials Market, Data Triangulation
FIGURE 5. Global mRNA Vaccine Raw Materials Market Size, 2017-2032 (USD Million)
FIGURE 6. Global mRNA Vaccine Raw Materials Market Size, by Material Type, 2025 vs 2032 (%)
FIGURE 7. Global mRNA Vaccine Raw Materials Market Size, by Material Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global mRNA Vaccine Raw Materials Market Size, by Delivery System, 2025 vs 2032 (%)
FIGURE 9. Global mRNA Vaccine Raw Materials Market Size, by Delivery System, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global mRNA Vaccine Raw Materials Market Size, by Process Stage, 2025 vs 2032 (%)
FIGURE 11. Global mRNA Vaccine Raw Materials Market Size, by Process Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global mRNA Vaccine Raw Materials Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global mRNA Vaccine Raw Materials Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global mRNA Vaccine Raw Materials Market Size, by End Use, 2025 vs 2032 (%)
FIGURE 15. Global mRNA Vaccine Raw Materials Market Size, by End Use, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global mRNA Vaccine Raw Materials Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global mRNA Vaccine Raw Materials Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global mRNA Vaccine Raw Materials Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global mRNA Vaccine Raw Materials Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global mRNA Vaccine Raw Materials Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global mRNA Vaccine Raw Materials Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global mRNA Vaccine Raw Materials Market Segmentation & Coverage
TABLE 2. Global mRNA Vaccine Raw Materials Market Size, 2017-2032 (USD Million)
TABLE 3. Global mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 4. Global Buffers Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Buffers Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Buffers Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Hepes Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Hepes Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Hepes Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Phosphate Buffer Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Phosphate Buffer Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Phosphate Buffer Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Tris Buffer Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Tris Buffer Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Tris Buffer Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Capping Enzymes Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Capping Enzymes Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Capping Enzymes Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Lipids Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Lipids Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Lipids Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Cholesterol Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Cholesterol Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Cholesterol Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Ionizable Lipids Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Ionizable Lipids Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Ionizable Lipids Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Pegylated Lipids Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Pegylated Lipids Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Pegylated Lipids Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Structural Lipids Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Structural Lipids Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Structural Lipids Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Nucleotide Triphosphates Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Nucleotide Triphosphates Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Nucleotide Triphosphates Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global ATP Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global ATP Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global ATP Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global CTP Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global CTP Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global CTP Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global GTP Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global GTP Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global GTP Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global UTP Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global UTP Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global UTP Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Purification Resins Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Purification Resins Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Purification Resins Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Affinity Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Affinity Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Affinity Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Ion Exchange Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Ion Exchange Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Ion Exchange Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Salt Reagents Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Salt Reagents Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Salt Reagents Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Potassium Chloride Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Potassium Chloride Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Potassium Chloride Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Sodium Chloride Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Sodium Chloride Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Sodium Chloride Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Solvents Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Solvents Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Solvents Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Ethanol Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Ethanol Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Ethanol Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Isopropanol Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Isopropanol Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Isopropanol Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 77. Global Exosome Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Exosome Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Exosome Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Engineered Exosomes Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Engineered Exosomes Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Engineered Exosomes Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Natural Exosomes Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Natural Exosomes Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Natural Exosomes Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Lipid Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Lipid Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Lipid Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Ionizable Lipid Particles Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Ionizable Lipid Particles Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Ionizable Lipid Particles Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Pegylated Lipid Particles Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Pegylated Lipid Particles Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Pegylated Lipid Particles Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Peptide Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Peptide Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Peptide Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Cell Penetrating Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Cell Penetrating Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Cell Penetrating Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Fusogenic Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Fusogenic Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Fusogenic Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Polymeric Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Polymeric Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Polymeric Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Chitosan Particles Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Chitosan Particles Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Chitosan Particles Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global PLGA Particles Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global PLGA Particles Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global PLGA Particles Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 114. Global Capping Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Capping Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Capping Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Filling And Finishing Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Filling And Finishing Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Filling And Finishing Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global Formulation Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Global Formulation Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. Global Formulation Market Size, by Country, 2017-2032 (USD Million)
TABLE 123. Global Purification Market Size, by Region, 2017-2032 (USD Million)
TABLE 124. Global Purification Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. Global Purification Market Size, by Country, 2017-2032 (USD Million)
TABLE 126. Global Synthesis Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Global Synthesis Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. Global Synthesis Market Size, by Country, 2017-2032 (USD Million)
TABLE 129. Global mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 130. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 133. Global COVID-19 Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Global COVID-19 Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. Global COVID-19 Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. Global Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Global Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. Global Influenza Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 139. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 140. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 142. Global Hematologic Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Global Hematologic Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. Global Hematologic Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 145. Global Solid Tumor Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Global Solid Tumor Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. Global Solid Tumor Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 148. Global mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 149. Global Human Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Global Human Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. Global Human Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 152. Global Veterinary Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Global Veterinary Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. Global Veterinary Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 155. Global mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 158. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 159. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 160. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 161. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 162. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 163. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 164. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 165. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 166. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 167. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 168. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 169. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 170. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 171. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 172. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 173. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 174. North America mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
TABLE 175. North America mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 176. North America mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 177. North America mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 178. North America mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 179. North America mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 180. North America mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 181. North America mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 182. North America mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 183. North America mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 184. North America mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 185. North America mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 186. North America mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 187. North America mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 188. North America mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 189. North America mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 190. North America mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 191. North America mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 192. Latin America mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
TABLE 193. Latin America mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 194. Latin America mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 195. Latin America mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 196. Latin America mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 197. Latin America mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 198. Latin America mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 199. Latin America mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 200. Latin America mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 201. Latin America mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 202. Latin America mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 203. Latin America mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 204. Latin America mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 205. Latin America mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 206. Latin America mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 207. Latin America mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 208. Latin America mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 209. Latin America mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 210. Europe mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
TABLE 211. Europe mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 212. Europe mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 213. Europe mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 214. Europe mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 215. Europe mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 216. Europe mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 217. Europe mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 218. Europe mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 219. Europe mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 220. Europe mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 221. Europe mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 222. Europe mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 223. Europe mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 224. Europe mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 225. Europe mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 226. Europe mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 227. Europe mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 228. Middle East mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
TABLE 229. Middle East mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 230. Middle East mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 231. Middle East mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 232. Middle East mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 233. Middle East mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 234. Middle East mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 235. Middle East mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 236. Middle East mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 237. Middle East mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 238. Middle East mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 239. Middle East mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 240. Middle East mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 241. Middle East mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 242. Middle East mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 243. Middle East mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 244. Middle East mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 245. Middle East mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 246. Africa mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
TABLE 247. Africa mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 248. Africa mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 249. Africa mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 250. Africa mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 251. Africa mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 252. Africa mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 253. Africa mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 254. Africa mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 255. Africa mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 256. Africa mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 257. Africa mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 258. Africa mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 259. Africa mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 260. Africa mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 261. Africa mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 262. Africa mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 263. Africa mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 264. Global mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
TABLE 265. ASEAN mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
TABLE 266. ASEAN mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 267. ASEAN mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 268. ASEAN mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 269. ASEAN mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 270. ASEAN mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 271. ASEAN mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 272. ASEAN mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 273. ASEAN mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 274. ASEAN mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 275. ASEAN mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 276. ASEAN mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 277. ASEAN mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 278. ASEAN mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 279. ASEAN mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 280. ASEAN mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 281. ASEAN mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 282. ASEAN mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 283. GCC mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
TABLE 284. GCC mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 285. GCC mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 286. GCC mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 287. GCC mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 288. GCC mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 289. GCC mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 290. GCC mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 291. GCC mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 292. GCC mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 293. GCC mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 294. GCC mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 295. GCC mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 296. GCC mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 297. GCC mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 298. GCC mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 299. GCC mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 300. GCC mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 301. European Union mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
TABLE 302. European Union mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 303. European Union mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 304. European Union mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 305. European Union mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 306. European Union mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 307. European Union mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 308. European Union mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 309. European Union mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 310. European Union mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 311. European Union mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 312. European Union mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 313. European Union mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 314. European Union mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 315. European Union mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 316. European Union mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 317. European Union mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 318. European Union mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 319. BRICS mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
TABLE 320. BRICS mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 321. BRICS mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 322. BRICS mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 323. BRICS mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 324. BRICS mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 325. BRICS mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 326. BRICS mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 327. BRICS mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 328. BRICS mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 329. BRICS mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 330. BRICS mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 331. BRICS mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 332. BRICS mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 333. BRICS mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 334. BRICS mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 335. BRICS mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 336. BRICS mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
TABLE 337. G7 mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
TABLE 338. G7 mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
TABLE 339. G7 mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
TABLE 340. G7 mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
TABLE 341. G7 mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
TABLE 342. G7 mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
TABLE 343. G7 mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
TABLE 344. G7 mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
TABLE 345. G7 mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
TABLE 346. G7 mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
TABLE 347. G7 mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 348. G7 mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
TABLE 349. G7 mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
TABLE 350. G7 mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
TABLE 351. G7 mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
TABLE 352. G7 mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 353. G7 mRNA Vaccine Raw Materials

Companies Mentioned

  • AGC Inc.
  • BioNTech SE
  • Catalent, Inc.
  • CureVac N.V.
  • Cytiva Life Sciences
  • Danaher Corporation
  • FUJIFILM Holdings Corporation
  • Ginkgo Bioworks Holdings, Inc.
  • Lonza Group AG
  • Maravai LifeSciences Holdings, Inc.
  • Merck KGaA
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Repligen Corporation
  • Sanofi S.A.
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies
  • WuXi Biologics Inc.

Related Topics

Related Reports

mRNA Vaccine Drugs Development Services Market - Global Forecast 2026-2032 - Product Image

mRNA Vaccine Drugs Development Services Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Report 2026 - Product Image

Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Report 2026

  • Report
  • 250 Pages
  • Global
From
mRNA Vaccines Market Report 2026-2036 - Product Image

mRNA Vaccines Market Report 2026-2036

  • Report
  • 241 Pages
  • Global
From
mRNA Vaccines Market - Global Forecast 2026-2032 - Product Image

mRNA Vaccines Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
mRNA Vaccines and Therapeutics Market Size, Share, Trends and Forecast by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2026-2034 - Product Image

mRNA Vaccines and Therapeutics Market Size, Share, Trends and Forecast by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2026-2034

  • Report
  • 146 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.